WHO Panel Weighs Ebola Vaccine Options for 500-Case DRC Outbreak
Updated
Updated · Reuters · May 19
WHO Panel Weighs Ebola Vaccine Options for 500-Case DRC Outbreak
6 articles · Updated · Reuters · May 19
A WHO-led expert panel meets Tuesday to assess whether any vaccines can be deployed against the Bundibugyo Ebola outbreak in eastern Democratic Republic of Congo.
The review comes after the outbreak reached 500 cases and 131 suspected deaths, prompting both the WHO and Africa CDC to declare a public health emergency.
No vaccine or treatment is approved for the Bundibugyo strain, which carries a fatality rate of up to 40%, forcing officials to consider experimental or indirect options.
Merck's Ervebo—approved for the Ebola Zaire strain—will be among candidates discussed after animal studies suggested it may offer some protection against Bundibugyo.
With Ebola now in Uganda, can a conflict-zone outbreak ever be truly contained?
Is deploying an unproven Ebola vaccine a desperate gamble or a necessary risk?
Bundibugyo Ebola Crisis 2026: Rapid Spread, No Vaccine, and the Race for Containment
Overview
As of May 19, 2026, the Bundibugyo Ebola outbreak is a serious and growing public health crisis. The World Health Organization warns that the outbreak may be much larger than currently known, based on high positivity rates in early samples and a rising number of suspected cases. This suggests the true scale of the disease is likely underestimated, making urgent and comprehensive action necessary. The full geographic spread is still being investigated, and international coordination is essential to understand the situation and respond effectively. These factors highlight the need for a strong, united global response to control the outbreak.